ointment vehicle-LEO Pharma-psoriasis vulgaris

ointment vehicle-LEO Pharma-psoriasis vulgaris refers to the inactive topical formulation used as a placebo control in clinical studies conducted by LEO Pharma, specifically for the treatment of psoriasis vulgaris. It represents the ointment base of the fixed-dose combination of calcipotriol and betamethasone dipropionate, excluding the active pharmaceutical ingredients. This vehicle was utilized in Phase 2 trials (such as NCT01536886) to provide a baseline for comparing the efficacy and safety of active treatments like LEO 90100 (calcipotriol/betamethasone dipropionate aerosol foam) and the standard calcipotriol/betamethasone ointment. As a vehicle, it lacks a specific biological mechanism of action and serves primarily as a carrier for topical application.

Brand names

Daivobet ointment vehicle

Other names

ointment vehicle